【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙

金吾资讯08-30

金吾财讯 | 四环医药(00460)公布，截至2024年6月30日止六个月，公司拥有人应占亏损3342.4万元(人民币，下同)，同比亏损收窄32.67%，每股基本亏损0.36分。派中期股息每股1.9分（相等于每股2.1港仙）。期内，集团收益9.50亿元，同比减少10.04%。其中来自医美产品的收益约3.23亿元，同比上升约66.4%；来自仿制药的收益约5.97亿元，同比下降约29.4%；来自创新药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2463278321?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-30 12:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2463278321","market":"hk","top_or_hot":-1,"title":"【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙","media":"金吾资讯","content":"<div>\n<p>金吾财讯 | 四环医药(00460)公布，截至2024年6月30日止六个月，公司拥有人应占亏损3342.4万元(人民币，下同)，同比亏损收窄32.67%，每股基本亏损0.36分。派中期股息每股1.9分（相等于每股2.1港仙）。期内，集团收益9.50亿元，同比减少10.04%。其中来自医美产品的收益约3.23亿元，同比上升约66.4%；来自仿制药的收益约5.97亿元，同比下降约29.4%；来自创新药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-30 12:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 四环医药(00460)公布，截至2024年6月30日止六个月，公司拥有人应占亏损3342.4万元(人民币，下同)，同比亏损收窄32.67%，每股基本亏损0.36分。派中期股息每股1.9分（相等于每股2.1港仙）。期内，集团收益9.50亿元，同比减少10.04%。其中来自医美产品的收益约3.23亿元，同比上升约66.4%；来自仿制药的收益约5.97亿元，同比下降约29.4%；来自创新药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSTECH","symbol_name":"恒生科技指数","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","article_id":"2463278321","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2463278321","pubTimestamp":1724991997,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"金吾财讯 | 四环医药 公布，截至2024年6月30日止六个月，公司拥有人应占亏损3342.4万元，同比亏损收窄32.67%，每股基本亏损0.36分。派中期股息每股1.9分。其中来自医美产品的收益约3.23亿元，同比上升约66.4%；来自仿制药的收益约5.97亿元，同比下降约29.4%；来自创新药及其他药品的收益约2960万元，同比上升约85.0%。期内，集团毛利6.09亿元，同比减少18.62%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSTECH":"恒生科技指数","07226":"XL二南方恒科","HSCEI":"国企指数","BK1515":"抗疫概念","BK1600":"工业大麻","BK1191":"制药","00460":"四环医药","BK1593":"医美概念股"},"translate_title":"[Hong Kong Stock Connect] Sihuan Pharmaceutical (00460) narrowed its mid-term loss by 32.67% and sent a mid-term Dividend of 2.1 Hong Kong cents","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1,"07226":1,"HSCEI":1,"HSTECH":1},"content_text":"金吾财讯 | 四环医药(00460)公布，截至2024年6月30日止六个月，公司拥有人应占亏损3342.4万元(人民币，下同)，同比亏损收窄32.67%，每股基本亏损0.36分。派中期股息每股1.9分（相等于每股2.1港仙）。期内，集团收益9.50亿元，同比减少10.04%。其中来自医美产品的收益约3.23亿元，同比上升约66.4%；来自仿制药的收益约5.97亿元，同比下降约29.4%；来自创新药及其他药品的收益约2960万元，同比上升约85.0%。期内，集团毛利6.09亿元，同比减少18.62%。期内研发开支约为1.96亿元，同比下降33.5%，主要由于集团研发管线中的多款产品（包括创新药、生物药及仿制药）的三期临床已陆续完成，其中部分产品已于2023陆续申请上市或已成功获批上市，同时本集团旗下生物医药子公司惠升生物的多个自研的产品已完成临床并已报产。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463278321"}